#United Kingdom #Novo Holdings #TA Associates #Biocomposites #Keele

Novo Holdings Partners with TA Associates to Propel Biocomposites' Growth

Novo Holdings and TA Associates have announced a strategic partnership through an investment in Biocomposites, a prominent player in the medical devices sector specializing in infection management solutions. As per the agreement, Novo Holdings, renowned for managing significant assets aimed at enhancing health and sustainability, will inject vital resources that promise to amplify Biocomposites' international reach and innovation in its product lineup.

Biocomposites, headquartered in Keele, United Kingdom, boasts over 30 years of experience in developing cutting-edge calcium compounds and polymer products used in both bone and soft tissue infection management. Known widely for its flagship product, STIMULAN, the company has established a strong reputation, earning the trust of surgeons across more than 100 countries. The unique formulation of STIMULAN, authorized to deliver antibiotics directly to both infected and non-infected sites, exemplifies the innovative solutions Biocomposites provides.

With its partnership with TA Associates beginning in 2017, Biocomposites has significantly escalated its growth trajectory, witnessing a threefold increase in revenue alongside a successful geographic expansion and product diversification. Moreover, the company has completed two pivotal acquisitions that further solidify its position in the international market and allow it to branch into related therapeutic areas.

The new investment from Novo Holdings comes at a critical juncture for Biocomposites, providing an opportunity to capitalize on its momentum and extend its global influence. The strategic focus will be on enhancing the pipeline of innovative products, which are crucial for improving the management of infections and, consequently, patient outcomes.

Henrik Kjær Hansen, Senior Partner at Novo Holdings, expressed enthusiasm about the alliance, emphasizing that Biocomposites’ commitment to transforming infection management aligns seamlessly with their own investment strategy in the life sciences sector. He articulated a firm belief in the company’s potential for growth and is eager to leverage Novo's extensive expertise and global connections to facilitate Biocomposites' expansion and innovation efforts.

In a similar vein, Michael Harris, CEO of Biocomposites, emphasized the importance of this investment, viewing it as validation of the company’s achievements and future prospects. He articulates optimism regarding the collaboration with both TA and Novo Holdings, foreseeing enhanced capabilities to introduce innovative infection management products to a broader audience, ultimately aiming to improve patient lives.

Birker Bahnsen, Managing Director at TA Associates also highlighted Biocomposites' outstanding journey as a pioneer in the infection management landscape, showcasing its successful international scaling and varied product offerings that align with the evolving healthcare market demands.

While the financial specifics of the transaction were not publicly disclosed, the comprehensive support from these leading global healthcare investors is expected to bolster Biocomposites' initiatives toward expanding their product offerings and market reach strategically.

With ongoing innovations and strategic investments, Biocomposites is also increasing its focus on surgical applications, operating across diverse specialties such as orthopaedics, trauma, and sports medicine. The prospects are aimed at not only enhancing their operational capabilities but also ensuring that they are at the forefront of infection management solutions.

As Biocomposites gears up for this new phase of growth, the combined efforts of Novo Holdings and TA Associates could signal significant advancements in the field of infection management, ultimately reshaping patient care on a global scale.

For more details regarding Biocomposites, you can visit Biocomposites' official website.